Table 4.
Exploration of the impact of BMI, race, and individual comorbid conditions on IWQOL-Kids scores for Teen-LABS participants by sex.
| FEMALES | Total | Physical Comfort | Body Esteem | Social Life | Family Relationsa | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value | |
| BMI | −0.34 (−0.62, −0.07) | 0.02 | −1.06 (−1.45, −0.67) | <0.01 | b | b | b | |||
| White race | −6.68 (−11.88, −1.49) | 0.01 | b | −10.47 (−18.68, −2.27) | 0.01 | b | b | |||
| DEPc | −15.69 (−22.09, −9.29) | <0.01 | −9.79 (−19.08, −0.50) | 0.04 | −23.94 (−34.24, −13.65) | <0.01 | −12.05 (−21.31, −2.78) | 0.01 | −0.19 (−0.32, −0.06) | <0.01 |
| BED | −10.07 (−16.53, −3.62) | <0.01 | −14.42 (−23.78, −5.07) | <0.01 | −10.85 (−21.15, −0.56) | 0.04 | −9.88 (−19.21, −0.54) | 0.04 | b | |
| PAIN | b | b | b | b | b | |||||
| OSA | b | b | b | b | −0.11 (−0.21, −0.01) | 0.03 | ||||
| PTC | b | b | b | −22.88 (−44.49, −1.28) | 0.04 | b | ||||
| CKD | b | b | b | −10.16 (−18.47, −1.86) | 0.02 | b | ||||
| Asthma | b | b | b | b | b | |||||
| CHOLITH | b | b | b | b | b | |||||
| SUI | b | −10.20 (−18.68, −1.71) | 0.02 | b | b | b | ||||
| MENST | −4.26 (−8.79, 0.27) | 0.07 | b | −6.45 (−13.62, 0.72) | 0.08 | b | b | |||
| Pseudo-R2 | 0.27 | 0.26 | 0.21 | 0.14 | 0.08 | |||||
| MALES | Total | Physical Comfort | Body Esteem | Social Life | Family Relationsa | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BMI | −0.49 (−0.87, −0.10) | 0.01 | −1.17 (−1.63, −0.71) | <0.01 | b | b | b | |||
| DEPc | −25.02 (−41.34, −8.72) | <0.01 | b | −35.76 (−61.04, −10.47) | <0.01 | −36.40 (−60.63, −12.16) | <0.01 | −0.12 (−0.22, −0.02) | 0.02 | |
| BED | b | b | b | b | b | |||||
| PAIN | −9.19 (−17.75, −0.63) | 0.04 | −15.53 (−25.17, −5.90) | <0.01 | b | b | b | |||
| GERD | b | −18.20 (−31.90, −4.50) | <0.01 | b | b | b | ||||
| DYSLIPID | −10.79 (−23.11, 1.53) | 0.09 | b | −17.73 (−37.69, 2.24) | 0.08 | −19.28 (−37.69, −0.87) | 0.04 | b | ||
| SUI | −31.11 (−40.84, −18.94) | <0.01 | b | −33.17 (−63.38, −2.95) | 0.03 | −37.93 (−69.97, −5.88) | 0.02 | b | ||
| Diabetes | b | b | b | −15.81 (−34.04, 2.04) | 0.09 | b | ||||
| CKD | b | b | b | b | b | |||||
| CHOLITH | b | b | b | b | −0.43 (−0.62, −0.23) | <0.01 | ||||
| Pseudo-R2 | 0.44 | 0.47 | 0.24 | 0.37 | 0.31 | |||||
BMI= Body Mass Index; BED= Binge Eating Disorder; CHOLITH= Cholelithiasis; CKD= Chronic Kidney Disease; DEP= Depression; DYSLIPID= Dyslipidemia; PAIN = Joint or Back Pain; GERD = Gastroesophageal Reflux Disorder; MENST= Menstrual Irregularities and polycystic ovary disease; OSA= Obstructive Sleep Apnea; PTC= Pseudotumor Cerebri; SUI=Stress Urinary Incontinence
Note: Variables not retained in the final models for any of the quality of life domains were not included in the table. For females: Diabetes, Fatty Liver Disease (FLD), Hypertension (Hyperten), DYSLIPID, GERD, and Blount’s Disease (Blounts). For males: White race, OSA, PTC, FLD, Hyperten, Asthma, and Blounts. Multivariable mixed-effect linear regression models, with clinical site as a random effect, were completed with imputed datasets (M=25) for females and males. Pseudo-R2 values refer to the proportion of the variance in the outcome explained by the set of predictor variables.
Log transformed.
Not included in final model.
Clinical range based on the Beck Depression Inventory-II total raw score ≥ 17